Drug intelligence / Profile preview

JW0106

Development stage: Unknown
Lead developer: JW Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

JW0106 is an investigational small molecule drug developed by JW Pharmaceutical. Its mechanism of action remains undisclosed and is currently classified as unknown or undefined. The drug is being studied primarily in combination with C2101, but also appears to be under investigation as a single agent. Clinical development has reached Phase I, with trials conducted in healthy volunteers in South Korea via the oral route of administration. No approved indications or known adverse events have been reported to date[1][2].

Other names: JW-0106JW0106JW 0106

Beyond the preview

Go deeper on JW0106.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JW0106.

Explore the full profile